Evidence map›Paper›PMID 34239716›Full record

ArticleOman medical journal2021

Featuring Trends in the Epidemiology of Lung Cancer Following the Publication of the National Cancer Strategy in Qatar.

Wanis H Ibrahim, Khalid Shariff, Mufid El Mistiri, Ussama Alhomsi, Awni Alshurafa, Khalid Farooqui, Mohammed E Faris, Khaled A Aboujabal, Kamel A Aboujabal, Hafedh Ghazouani and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oman medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Wanis H IbrahimDepartment of Medicine, Hamad General Hospital, Doha, Qatar.
Khalid ShariffDepartment of Medicine, Hamad General Hospital, Doha, Qatar.
Mufid El MistiriHamad Medical Corporation, National Center for Cancer Care and Research, Doha, Qatar.
Ussama AlhomsiHamad Medical Corporation, National Center for Cancer Care and Research, Doha, Qatar.
Awni AlshurafaDepartment of Medicine, Hamad General Hospital, Doha, Qatar.
Khalid FarooquiDepartment of Medicine, Hamad General Hospital, Doha, Qatar.
Mohammed E FarisDepartment of Medicine, Hamad General Hospital, Doha, Qatar.
Khaled A AboujabalMedical Student, College of Medicine, Qatar University, Doha, Qatar.
Kamel A AboujabalMedical Student, College of Medicine, Qatar University, Doha, Qatar.
Hafedh GhazouaniDepartment of Medicine, Hamad General Hospital, Doha, Qatar.
Raza A AkbarDepartment of Medicine, Hamad General Hospital, Doha, Qatar.
Muhammad A WaheedDepartment of Medicine, Northampton General Hospital, Northampton, UK.
Reyad H MohsenHamad Medical Corporation, National Center for Cancer Care and Research, Doha, Qatar.
Mohsen EledrisiDepartment of Medicine, Hamad General Hospital, Doha, Qatar.
Hamad General Hospital · QANational Center for Cancer Care and Research · QAHamad Medical Corporation · QANorthampton General Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesQatar has witnessed significant reforms in its health care system, including the care of cancer patients. In 2011, the National Cancer Strategy was released with the aim to deliver a high standard of care to cancer patients across the country. We sought to investigate the featuring trends in the epidemiological and clinical characteristics of lung cancer in Qatar following the publication of the National Cancer Strategy.

methodsWe conducted a retrospective cohort study documenting the epidemiological and clinical characteristics of primary lung cancer cases in Qatar diagnosed from 1 January 2011 to 31 December 2018.

resultsThe overall age-standardized incidence rate was 8.7 per 100 000 persons (11.6 per 100 000 and 5.4 per 100 000 persons for males and females, respectively). The one, three, and five-year overall survival rates were 67.0%, 48.0%, and 28.0%, respectively. The three-year overall survival rates for stages I, II, III, and IV were 97.0%, 78.0%, 52.0%, and 31.0%, respectively. The three-year survival rates for males and females were 43.0% and 64.0%, respectively (

conclusionsDespite the low overall lung cancer incidence rate in Qatar, there is a rise in the incidence among females when compared to previous studies. Qatar has favorable five-year lung cancer survival rates compared to many developed and neighboring countries. Policymakers in the country should consider the changing patterns in lung cancer incidence when planning future preventive strategies.

Indexed as

Delivery of Health CareIncidenceLung NeoplasmsQatarRetrospective StudiesSurvival Rate

Identifiers

PMID34239716
PMCPMC8237402
OpenAlexW3173273631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.